Myomo (MYO) Net Income towards Common Stockholders Growth (1y) (2017 - 2025)
Myomo (MYO) Net Income towards Common Stockholders Growth (1y) (2017 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.32 Bn | 175.02 Bn | 6.27 Bn | -18.72% |
| 2 | Stryker | 128.75 Bn | 125.88 Bn | 3.81 Bn | 13.91% |
| 3 | Medtronic | 107.83 Bn | 98.61 Bn | 6.41 Bn | 18.55% |
| 4 | Boston Scientific | 67.61 Bn | 66.15 Bn | 3.61 Bn | 98.96% |
| 5 | Edwards Lifesciences | 48.13 Bn | 44.45 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn | 89.28% |
| 7 | GE HealthCare Technologies | 27.78 Bn | 25.50 Bn | 1.98 Bn | -30.10% |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - | - |
| 9 | Koninklijke Philips | 23.92 Bn | 20.80 Bn | 2.07 Bn | 121.14% |
| 10 | Myomo | 43.43 Mn | 24.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -279.02% |
| Jun 30, 2025 | -312.98% |
| Mar 31, 2025 | 9.66% |
| Dec 31, 2024 | 366.85% |
| Sep 30, 2024 | 52.37% |
| Jun 30, 2024 | -10.60% |
| Mar 31, 2024 | -45.05% |
| Dec 31, 2023 | -128.39% |
| Sep 30, 2023 | 28.30% |
| Jun 30, 2023 | 65.14% |
| Mar 31, 2023 | 6.06% |
| Dec 31, 2022 | 356.86% |
| Sep 30, 2022 | -37.56% |
| Jun 30, 2022 | -10.97% |
| Mar 31, 2022 | 4.93% |
| Dec 31, 2021 | -98.61% |
| Sep 30, 2021 | 25.92% |
| Jun 30, 2021 | 20.25% |
| Mar 31, 2021 | 33.80% |
| Dec 31, 2020 | 38.50% |